FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1α

Neoplasma

Volumn 64, Issue 4, 2017, Pages 535-542

  Shi, L ^a   He, C ^a   Li, Z ^a   Wang, Z ^a   Zhang, Q ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

6 bisphosphatase 1; Basal like breast carcinoma; Fructose 1; Glucose metabolism; Hypoxia inducible factor 1

Indexed keywords

FRUCTOSE 1,6 BISPHOSPHATASE 1; FRUCTOSE BISPHOSPHATASE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; LDHA PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; SLC2A1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CELL METABOLISM; CELL MIGRATION; CELL MIGRATION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LENTIVIRINAE; METABOLIC ACTIVITY ASSAY; MTT ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL HYPOXIA; GENETICS; GLYCOLYSIS; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; FRUCTOSE-BISPHOSPHATASE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; L-LACTATE DEHYDROGENASE; PROTEIN-SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85024099979     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2017_407     Document Type: Article

References (39)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. https://doi.org/10.3322/caac.20107
2. LECH R, PRZEMYSLAW O. Epidemiological models for breast cancer risk estimation. Ginekol Pol 2011; 82: 451–454.
3. PEROU CM, SORLIE T, EISEN MB, VAN DE RIJN M, JEFFREY SS et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752. https://doi. org/10.1038/35021093
4. SORLIE T, PEROU CM, TIBSHIRANI R, AAS T, GEISLER S et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869–10874. https://doi.org/10.1073/pnas.191367098
5. LUNDGREN K, NORDENSKJ LD B, LANDBERG G. Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer. Br J Cancer 2009; 101: 1769–1781. https://doi.org/10.1038/sj.bjc.6605369
6. VAUPEL P, MAYER A, HOCKEL M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335–354. https://doi.org/10.1016/S0076-6879(04)81023-1
7. VAUPEL P, SCHLENGER K, KNOOP C, HOCKEL M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51: 3316–3322.
8. SEMENZA GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365: 537–547. https://doi.org/10.1056/NEJMra1011165
9. GERMAIN S, MONNOT C, MULLER L, EICHMANN A. Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding. Curr Opin Hematol 2010; 17: 245–251. https://doi.org/10.1097/moh.0b013e32833865b9
10. WANG GL, JIANG BH, RUE EA, SEMENZA GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510–5514. https://doi.org/10.1073/pnas.92.12.5510
11. SCHOFIELD CJ, RATCLIFFE PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–354. https://doi.org/10.1038/nrm1366
12. VAUPEL P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9 Suppl 5: 10–17. https://doi.org/10.1634/theoncologist.9-90005-10
13. POUYSSEGUR J, DAYAN F, MAZURE NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437–443. https://doi.org/10.1038/na-ture04871
14. RAKHA EA, ELSHEIKH SE, ALESKANDARANY MA, HABASHI HO, GREEN AR et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302–2310. https://doi. org/10.1158/1078-0432.CCR-08-2132
15. TAN EY, YAN M, CAMPO L, HAN C, TAKANO E et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 2009; 100: 405–411. https://doi.org/10.1038/sj.bjc.6604844
16. CANCER GENOME ATLAS NETWORK. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70. https://doi.org/10.1038/nature11412
17. KOPPENOL WH, BOUNDS PL, DANG CV. Otto Warburg‘s contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325–337. https://doi.org/10.1038/nrc3038
18. WEIDEMANN A, JOHNSON RS. Biology of HIF-1α. Cell Death Differ 2008; 15: 621–627. https://doi.org/10.1038/cdd.2008.12
19. MIZUNUMA H, TASHIMA Y. Fructose-1,6-biphosphatase of the small intestine. Purification and comparison with liver and muscle fructose-1,6-bisphosphatases. J Biochem 1978; 84: 327–336. https://doi.org/10.1093/oxfordjournals.jbchem. a132132
20. TILLMANN H, ESCHRICH K. Isolation and characterization of an allelic cDNA for human muscle fructose-1,6-bisphos-phatase. Gene 1998; 212: 295–304. https://doi.org/10.1016/S0378-1119(98)00181-4
21. CHEN M, ZHANG J, LI N, QIAN Z, ZHU M et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One 2011; 6: e25564. https://doi.org/10.1371/journal. pone.0025564
22. LIU X, WANG X, ZHANG J, LAM EK, SHIN VY et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010; 29: 442–450. https://doi.org/10.1038/onc.2009.332
23. LI B, QIU B, LEE DS, WALTON ZE, OCHOCKI JD et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 2014; 513: 251–255. https://doi.org/10.1038/nature13557
24. BIGL M, JANDRIG B, HORN LC, ESCHRICH K. Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer. Biochem Biophys Res Commun 2008; 377: 720–724. https://doi.org/10.1016/j. bbrc.2008.10.045
25. ZENG Z, ZHANG C, CHEN J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts. J Bone Miner Metab 2013; 31: 409–416. https://doi.org/10.1007/s00774-013-0434-0
26. GENERALI D, BERRUTI A, BRIZZI MP, CAMPO L, BONARDI S et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006; 12: 4562–4568. https://doi. org/10.1158/1078-0432.CCR-05-2690
27. ZHONG H, DE MARZO AM, LAUGHNER E, LIM M, HILTON DA et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830–5835.
28. TALKS KL, TURLEY H, GATTER KC, MAXWELL PH, PUGH CW et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411–421. https://doi.org/10.1016/S0002-9440(10)64554-3
29. TRASTOUR C, BENIZRI E, ETTORE F, RAMAIOLI A, CHAMOREY E et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007; 120: 1451–1458. https://doi.org/10.1002/ijc.22436
30. HUBBI ME, SEMENZA GL. Regulation of cell Pprolif-eration by hypoxia-inducible factors. Am J Physiol Cell Physiol 2015; 309: C775–782. https://doi.org/10.1152/ajpcell.00279.2015
31. TIAN Q, XUE Y, ZHENG W, SUN R, JI W et al. Overexpression of hypoxia-inducible factor 1α induces migration and invasion through Notch signaling. Int J Oncol 2015; 47: 728–738. https://doi.org/10.3892/ijo.2015.3056
32. TENNANT DA, DURAN RV, GOTTLIEB E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10: 267–277. https://doi.org/10.1038/nrc2817
33. BAKER L, BOULT J, WALKER-SAMUEL S, CHUNG Y, JA-MIN Y et al. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer 2012; 106: 1638–1647. https://doi.org/10.1038/bjc.2012.131
34. IYER NV, KOTCH LE, AGANI F, LEUNG SW, LAUGHNER E et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 1998; 12: 149–162. https://doi.org/10.1101/gad.12.2.149
35. KIM JW, TCHERNYSHYOV I, SEMENZA GL, DANG CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177–185. https://doi.org/10.1016/j. cmet.2006.02.002
36. WARD PS, THOMPSON CB. Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 2012; 4: a006783.
37. BEHROOZ A, ISMAIL-BEIGI F. Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem 1997; 272: 5555–5562. https://doi.org/10.1074/jbc.272.9.5555
38. FORSYTHE JA, JIANG BH, IYER NV, AGANI F, LEUNG SW et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604–4613. https://doi.org/10.1128/MCB.16.9.4604
39. RAPISARDA A, MELILLO G. Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy. Adv Cancer Res 2012; 114: 237–267. https://doi.org/10.1016/B978-0-12-386503-8.00006-5